

Multi-Tier Enhanced Annual Drug List Updates

July 2019

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
AIMOVIG (ereumab-aooe subcutaneous soln auto-injector 140 mg/ml)	Brand	Addition
NIVESTYM (filgrastim-aafi inj 300 mcg/ml)	Brand	Addition
NIVESTYM (filgrastim-aafi inj 480 mcg/1.6ml (300 mcg/ml))	Brand	Addition
REVOVI (elapegademase-lvlr im soln 2.4 mg/1.5ml (1.6 mg/ml))	Brand	Addition
TRESIBA (insulin degludec inj 100 unit/ml)	Brand	Addition
UDENYCA (pegfilgrastim-cbqv soln prefilled syringe 6 mg/0.6ml)	Brand	Addition
VENCLEXTA (venetoclax tab 10 mg)	Brand	Addition
VENCLEXTA (venetoclax tab 100 mg)	Brand	Addition
VENCLEXTA (venetoclax tab 50 mg)	Brand	Addition
VENCLEXTA STARTING PACK (venetoclax tab therapy starter pack 10 & 50 & 100 mg)	Brand	Addition

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.